Literature DB >> 12862196

Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial.

Shelby D Reed1, Joëlle Y Friedman, Ari Gnanasakthy, Kevin A Schulman.   

Abstract

OBJECTIVES: To develop and evaluate strategies for estimating hospitalization costs in multinational clinical trials.
METHODS: Hospital cost estimates for eleven diagnoses were collected from twelve countries participating in a trial of therapies for congestive heart failure. Estimates were combined with U.S.-based diagnosis-related group weights to compute country-specific unit cost estimates for all reasons for hospitalization. Variations of hospital costing methods were developed. The unit cost method assigns a country-specific unit cost estimate to each hospitalization. The other methods adjust for length of stay using a daily cost (DC) estimate for each diagnosis, based on either the mean length of stay (DC-mean method) or the median length of stay (DC-median method) for each diagnosis in each country. Additional modifications were explored through adjustment of the distribution of daily costs incurred during a hospital stay.
RESULTS: The mean cost for all hospitalizations was dollars 10,242 (SD, 10,042) using the unit cost method, dollars 10,242 (SD, 12,760) using the standard DC-mean method, and dollars 13,967 (SD, 18,762) using the standard DC-median method. In comparisons of costs for all 5,486 hospitalizations incurred by a subset of 2,352 patients in the trial, the unit cost method provided 92% power to detect a dollars 1,000 cost difference. The standard DC-mean method provided 76% power, and the standard DC-median method provided 44% power.
CONCLUSIONS: Hospital costing methods that adjust for differences in length of stay require a significantly larger sample to attain comparable statistical power as methods that assign unadjusted unit cost estimates to hospitalization events.

Entities:  

Mesh:

Year:  2003        PMID: 12862196     DOI: 10.1017/s0266462303000357

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Authors:  Shelby D Reed; Yanhong Li; Helen A Dakin; Frauke Becker; Jose Leal; Stephanie M Gustavson; Bernt Kartman; Eric Wittbrodt; Robert J Mentz; Neha J Pagidipati; M Angelyn Bethel; Alastair M Gray; Rury R Holman; Adrian F Hernandez
Journal:  Diabetes Care       Date:  2019-12-05       Impact factor: 19.112

3.  Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.

Authors:  Shelby D Reed; Jasmina I Radeva; Davey B Daniel; Samir H Mody; Jamie B Forlenza; R Scott McKenzie; Kevin A Schulman
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Comparisons of hypertension-related costs from multinational clinical studies.

Authors:  C Daniel Mullins; Mirko Sikirica; Viran Seneviratne; Jeonghoon Ahn; Kasem S Akhras
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Costing and cost analysis in randomized controlled trials: caveat emptor.

Authors:  Daniel Polsky; Henry Glick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Basing care reforms on evidence: the Kenya health sector costing model.

Authors:  Steffen Flessa; Michael Moeller; Tim Ensor; Klaus Hornetz
Journal:  BMC Health Serv Res       Date:  2011-05-27       Impact factor: 2.655

7.  Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016.

Authors:  Mark W Moses; Paola Pedroza; Ranju Baral; Sabina Bloom; Jonathan Brown; Abby Chapin; Kelly Compton; Erika Eldrenkamp; Nancy Fullman; John Everett Mumford; Vishnu Nandakumar; Katherine Rosettie; Nafis Sadat; Tom Shonka; Abraham Flaxman; Theo Vos; Chris J L Murray; Marcia R Weaver
Journal:  Lancet Public Health       Date:  2018-12-12

8.  Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Authors:  Joanna C Thorn; Emma L Turner; Luke Hounsome; Eleanor Walsh; Liz Down; Julia Verne; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin; Sian M Noble
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.